Skip to main content
Indegene Limited logo

Indegene Limited — Investor Relations & Filings

Ticker · INDGN ISIN · INE065X01017 LEI · 335800XFEREFIW9LG995 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country IN India
Listing BSE.NS INDGN

About Indegene Limited

https://www.indegene.com/

Indegene Limited provides digital-led commercialization services for the life sciences sector. The company integrates deep domain knowledge with proprietary technology platforms to assist biopharmaceutical, emerging biotech, and medical device organizations. Its core offerings span the entire product lifecycle, including clinical development support, regulatory compliance, pharmacovigilance, and multi-channel marketing operations. By leveraging artificial intelligence and machine learning, Indegene enables clients to optimize drug development processes, enhance patient engagement, and drive operational efficiencies. The company focuses on modernizing traditional commercial models through data-driven insights and digital transformation strategies, helping global healthcare organizations navigate complex regulatory environments and improve health outcomes through scaled, technology-enabled solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-04-21 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a notification of a scheduled Board Meeting to approve and take on record audited financial results and other corporate actions. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about Board Meetings. The document does not contain the financial results themselves but informs about the upcoming meeting where these results will be approved. The document length is short (2241 characters) and serves as an announcement rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about a Board Meeting and not the actual financial report or management information.
2026-04-21 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details of securities dematerialized/rematerialized for the quarter ended March 31, 2026. It is a compliance confirmation letter from the Registrar and Transfer Agent (RTA) to the company and stock exchanges. The document is short (3318 characters) and serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is primarily a regulatory filing confirming compliance with SEBI regulations related to securities dematerialization. Therefore, it fits best under Regulatory Filings (RNS).
2026-04-09 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to announcements of material events or agreements by listed companies. It details a Trade and Asset Purchase Agreement between Indegene Healthcare UK Limited and Trilogy Writing and Consulting Limited, including specifics of the transaction and related party status. The document is an announcement of a transaction rather than a financial report, audit, or management discussion. It does not contain financial statements or detailed financial analysis but rather a regulatory disclosure of a corporate event. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business acquisition and asset purchase agreement disclosure.
2026-04-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window for insiders due to the upcoming finalization and approval of financial results for the fiscal year ending March 31, 2026. It references SEBI regulations on insider trading and advises designated persons not to trade during this period. The document does not contain any financial data, results, or detailed report content. It is a regulatory announcement related to insider trading restrictions ahead of financial results disclosure. The document length is short (1907 characters) and serves as an intimation rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-03-27 English
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about resolutions passed by the Board of Directors regarding allotment of shares under the RSU 2020 plan. It is an announcement of board decisions related to share allotment, which pertains to capital structure changes. The document is short (1470 characters) and does not contain financial statements or detailed financial data. Therefore, it is not a full financial report but an update on capital/financing activities. Hence, the appropriate classification is Capital/Financing Update (CAP).
2026-03-18 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.